The 6th Consortium Meeting of imSAVAR was successfully held at Fraunhofer IZI in Leipzig, closely following the Leipzig Immune Oncology (LION) Conference 2024. This timing allowed us to seamlessly continue the inspiring discussions initiated at the conference, bringing together our Consortium Partners to discuss progress, challenges, and future directions for the project.
The meeting commenced with a warm welcome from coordinators Kristin Reiche and Hannah Morgan. Participants engaged in meaningful discussions about the current status and future plans of our work packages. Key highlights included presentations on the Tumor-on-a-Chip and Vessel-on-a-Chip initiatives, as well as updates on irAOP and Biomarkers. Day one concluded with a social event, where attendees enjoyed a guided city tour through the beautiful streets of Leipzig, gaining fresh perspectives on this vibrant city that hosts our collaboration. This provided an excellent opportunity for networking and relaxation.
The second day began with a recap of imSAVAR’s objectives, underscoring the project’s mission and progress. Following this, EFPIA presented the latest results, along with expectations and outlooks for the remainder of the project and beyond.
Next, we organized a Mini-Study-a-Thon focusing on data transfer, sharing, and integration. This interactive session encouraged practical engagement and addressed frequently asked questions.
After a lunch break and poster session, we had a fantastic opportunity to share insights, review our progress in objectives, and align our strategies for the final phase of our project. The atmosphere was filled with a collaborative spirit and innovative ideas. We are excited to share that we’ve already begun brainstorming initial concepts for a follow-up project, which is crucial for ensuring the sustainability of our work beyond the official Innovative Health Initiative (IHI) funding.
A heartfelt thank you to the amazing organizational team at Fraunhofer IZI and all participants for your valuable contributions and unwavering dedication to our shared goals. Together, we are making significant strides towards safer immune therapies!
Overall, the 6th Consortium Meeting of imSAVAR provided a vital platform for collaboration, knowledge exchange, and strategic planning, and we look forward to our continued collaboration and the exciting developments that lie ahead!
